P. vivax merozoite surface protein Selleckchem GSK1349572 9 is a promising vaccine candidate antigen. Previous studies have demonstrated that (i) PvMSP9 is conserved among mice, primate and human Plasmodium species [12]; (ii) PvMSP9 recombinant proteins induce high titers of antibodies [13]; (iii) antibodies raised against PvMSP9 are capable of inhibiting merozoite invasion [12]; and (iv) malaria-exposed individuals present high frequency of natural antibody and cellular immune response against different regions of PvMSP9 [14]. Clinical trials based on a few selected malaria antigens have shown limited immunogenicity and a failure to induce

long-lasting immunity, possibly due to the lack of effective T-cell epitopes in the constructs used as immunogens [16] and [17]. Nevertheless, there have been only a few T-cell epitopes reported from malaria antigens [18], [19], [20], [21], [22], [23] and [24]. A major obstacle for identifying T-cell epitopes is the high level of polymorphism of HLA class II molecules. Thus, one of the most relevant steps for malaria vaccine development is to define T-cell epitopes that can interact promiscuously with a broad range of HLA-DR and/or HLA-DQ molecules. Here we present the identification of five T-cell epitopes in the vaccine candidate PvMSP9 that are capable of stimulating T cells from donors expressing

various HLA genotypes and GS-7340 purchase with confirmed exposure to P. vivax infections. Experimental screening methods to evaluate the presence of HLA restriction in immune response to vaccine candidates are expensive and time consuming. Computational prediction methods complement experimental studies, minimize the number of validation experiments, and significantly expedite the epitope mapping process [11]. Such methods have helped

identify promiscuous epitopes within Leishmania [25], Mycobacterium tuberculosis [26] and HIV [27] antigens. Several promiscuous epitopes from pre-erythrocytic [22], [23] and [28], asexual blood-stage [21], [24] and [29], and gametocyte [20] antigens have been predicted and/or Olopatadine experimentally confirmed for P. falciparum. In contrast, only limited studies have focused on promiscuous epitopes for P. vivax [19], [30], [31] and [32]. In our study, eleven peptides were predicted by the ProPred algorithm to be promiscuous, but only five of them were recognized at high frequency by PBMCs from individuals living in malaria endemic areas. The recall response elicited by at least one of these five peptides was high for both IFN-γ (64.1%) and for IL-4 (50.7%) in comparison with the frequencies observed for other Plasmodium antigens such as PvTRAg40 [33], PfTRAP [34], PvDBP [35]. The frequency of T cells reactive to PvMSP9 is comparable to a study by Farouk et al. [36] that measured the cellular response to crude P. falciparum antigens by ELISPOT in a Malian population.